Helixgate https://validator.w3.org/feed/docs/rss2.html Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms Home Tau and Alzheimer’s Disease STAT+: Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments STAT+: FDA approves Replimune melanoma drug previously rejected twice Renewed Importance of CEX in Monoclonal-Antibody Purification STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts Erica Schwartz confirmed as CDC director, filling nearly yearlong vacancy BioVie shares halve on murky Parkinson’s disease readout Takeda approval ushers in new wave of sleep drugs Tau Protein Linked to Mitochondrial Reverse Electron Transport in Preclinical Models Erica Schwartz confirmed as next CDC director Lilly confident in slow and steady Foundayo launch, as ex-US sales shine Braveheart pumps more life into biotech IPO market with $382M expected debut STAT+: Two FDA approvals — a new drug and a new vaccine With $263M, LifeMine unearths a new drug for organ transplants Takeda’s narcolepsy nod opens orexin doors Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’ Lilly, FDA retatrutide biologic dispute comes to a head as submission nears Opinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he was DNA Script Wins ARPA-H Award to Advance DNA Manufacturing Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock LifeMine raises $263M in mission to improve organ transplant aftercare FDA approves Moderna’s mRNA flu vaccine The next treatment-resistant depression paradigm Lilly climbs, Novo falls as obesity drug battle intensifies Opinion: What my colleagues and I will look for as we assess U.S. measles elimination status Opinion: Stop asking if AI is good for medicine CROs vs. biotechs: Finding the right fit The top 12 companies hiring in biopharma now COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVID STAT+: Could poop pills be the next treatment for food allergies? STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety Attovia adds to biotech IPO momentum with $289M offering Immune Pathway Identified That Prevents C. albicans Infection from Becoming Deadly Electrical Stimulation’s Effects on Neurons, Gene Expression Mapped in Living Human Brain Tissue No deal between AstraZeneca and BMS, senior source insists: Reuters Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees Over 1/3 stay in biopharma jobs for health insurance, poll finds Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’ Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts STAT+: Moderna launches early trial of Ebola mRNA vaccine Targeted therapy shows promise in advanced colorectal cancer Novo CEO sees innovation as a matter of survival amid pipeline setbacks Enzene Targets Local Biomanufacturing with New Solutions A COPD drug from China draws $115M in venture funding The main therapy used for children with autism faces changes under Medicaid FDA approves Moderna’s mRNA flu vaccine, the first to use the technology Engineered macrophages with IL-10–TLR9 signal switch receptors for reprogramming tumor microenvironment and enhancing antitumor immunity